Marvin Jonathan S, Zhu Zhenping
Department of Antibody Technology, ImClone Systems Incorporated, New York, NY 10014, USA.
Acta Pharmacol Sin. 2005 Jun;26(6):649-58. doi: 10.1111/j.1745-7254.2005.00119.x.
One of the major obstacles in the development of bispecific antibodies (BsAb) has been the difficulty of producing the materials in sufficient quality and quantity by traditional technologies, such as the hybrid hybridoma and chemical conjugation methods. In contrast to the rapid and significant progress in the development of recombinant BsAb fragments (such as diabody and tandem single chain Fv), the successful design and production of full length IgG-like BsAb has been limited. Compared to smaller fragments, IgG-like BsAb have long serum half-life and are capable of supporting secondary immune functions, such as antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. The development of IgG-like BsAb as therapeutic agents will depend heavily on our research progress in the design of recombinant BsAb constructs (or formats) and production efficiency. This review will focus on recent advances in various recombinant approaches to the engineering and production of IgG-like BsAb.
双特异性抗体（BsAb）研发过程中的主要障碍之一是，通过传统技术（如杂交杂交瘤技术和化学偶联方法）难以生产出质量和数量都足够的产品。与重组BsAb片段（如双体和串联单链Fv）研发方面迅速且显著的进展相比，全长IgG样BsAb的成功设计和生产一直受到限制。与较小的片段相比，IgG样BsAb具有较长的血清半衰期，并且能够支持诸如抗体依赖性细胞毒性和补体介导的细胞毒性等二级免疫功能。将IgG样BsAb开发为治疗剂将在很大程度上取决于我们在重组BsAb构建体（或形式）设计和生产效率方面的研究进展。本综述将聚焦于IgG样BsAb工程化和生产的各种重组方法的最新进展。
